ArticleOncology2024

Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.

Changwan Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.